Company Description
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States.
The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
The company’s products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn’s disease (CD).
The company was incorporated in 2022 and is based in San Carlos, California.
| Country | United States |
| Founded | 2023 |
| IPO Date | Aug 5, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Tao Fu |
Contact Details
Address: 1091 Industrial Road, Suite 310 San Carlos, California 94070 United States | |
| Phone | 510 399 5001 |
| Website | attovia.com |
Stock Details
| Ticker Symbol | ATTO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 2058707 |
| CUSIP Number | 04987L102 |
| ISIN Number | US04987L1026 |
| Employer ID | 92-1510574 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Tao Fu | Chief Executive Officer, President and Director |
| Zaneta Odrowaz, Ph.D. | Chief Business Officer, Treasurer, Secretary |
| Steven Chan | Chief Financial Officer |
| Petter Veiby | Chief Scientific Officer |
| Hubert Chen, M.D. | Chief Medical Officer |
| James Topper, M.D., Ph.D. | Chairman and Director |
| Mitchell Gold, M.D. | Director |
| Rebecca Luse. | Director |
| Aaron Royston, M.D. | Director |
| John W. Smither | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2026 | SCHEDULE 13G | Filing |
| Aug 11, 2026 | SCHEDULE 13D | Filing |
| Aug 6, 2026 | 4 | Statement of changes in beneficial ownership of securities |
| Aug 6, 2026 | 4 | Statement of changes in beneficial ownership of securities |
| Aug 6, 2026 | 8-K | Current Report |
| Aug 6, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 5, 2026 | 424B4 | Prospectus |
| Aug 4, 2026 | EFFECT | Notice of Effectiveness |
| Aug 4, 2026 | 3 | Initial statement of beneficial ownership of securities |
| Aug 4, 2026 | 3 | Initial statement of beneficial ownership of securities |